Bone marrow‐derived progenitor cells in de novo liver regeneration in liver transplant

Sung‐Gyu Lee, Sung‐Hwan Moon, Hee‐Je Kim, Ji Yoon Lee, Soon‐Jung Park, Hyung‐Min Chung, Tae‐Yong Ha, Gi‐Won Song, Dong‐Hwan Jung, Hojong Park, Tae‐Won Kwon, Yong‐Pil Cho – 11 March 2015 – The study was designed (1) to examine the hypothesis that circulating progenitor cells play a role in the process of de novo regeneration in human liver transplants and that these cells arise from a cell population originating in, or associated with, the bone marrow and (2) to investigate whether the transplanted liver volume has an effect on the circulating recipient‐derived progenitor cells that generate

Serostatus following live attenuated vaccination administered before pediatric liver transplantation

Takanori Funaki, Kensuke Shoji, Ippei Miyata, Seisuke Sakamoto, Mureo Kasahara, Hironori Yoshii, Isao Miyairi, Akihiko Saitoh – 11 March 2015 – After liver transplantation (LT), live attenuated vaccines (LAVs) are generally contraindicated. LAVs are recommended before LT for patients ≥ 6 months of age. However, the evidence supporting this practice is limited. Patients were enrolled before and after LT. Clinical data for patients were obtained from medical records. Serum antibody titers were evaluated at the time of enrollment and prospectively.

Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers

Ravi Chhatrala, M. Bilal Siddiqui, R. Todd Stravitz, Carolyn Driscoll, Arun Sanyal, Carol Sargeant, Velimir Luketic, Amit Sharma, Richard Sterling, Scott Matherly, Puneet Puri, M. Shadab Siddiqui – 11 March 2015 – Although cardiovascular disease (CVD) is the leading cause of long‐term mortality in liver transplant recipients (LTRs), the role of recently identified biomarkers of CVD risk in liver transplantation is unknown. We aimed to evaluate an extensive CVD risk profile in LTRs.

Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation

Joanna Stefaniak, Judith Schiefer, Edmund John Miller, Claus Georg Krenn, David Marek Baron, Peter Faybik – 11 March 2015 – Acute kidney injury (AKI) after orthotopic liver transplantation (OLT) is associated with a poor clinical outcome. Because there is no specific treatment for postoperative AKI, early recognition and prevention are fundamental therapeutic approaches. Concentrations of the proinflammatory cytokine macrophage migration inhibitory factor (MIF) are elevated in patients with kidney disease.

Increased duodenal iron absorption through up‐regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis

Toshifumi Hoki, Koji Miyanishi, Shingo Tanaka, Kohichi Takada, Yutaka Kawano, Akira Sakurada, Masanori Sato, Tomohiro Kubo, Tsutomu Sato, Yasushi Sato, Rishu Takimoto, Masayoshi Kobune, Junji Kato – 7 March 2015 – Increased hepatic iron accumulation is thought to be involved in the pathogenesis of nonalcoholic steatohepatitis (NASH). Hepatic iron accumulation, as well as oxidative DNA damage, is significantly increased in NASH livers. However, the precise mechanism of iron accumulation in the NASH liver remains unclear.

Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in Medicare patients

Viktor V. Chirikov, Fadia T. Shaya, Charles D. Howell – 7 March 2015 – Patient‐ and county‐level characteristics associated with advanced liver disease (ALD) at hepatitis C virus (HCV) diagnosis were examined in three Medicare cohorts: (1) elderly born before 1945; (2) disabled born 1945‐1965; and (3) disabled born after 1965. We used Medicare claims (2006‐2009) linked to the Area Health Resource Files. ALD was measured over the period of 6 months before to 3 months after diagnosis.

Subscribe to